Jeffrey Alan Sosman
Northwestern University · 971 works · 129,175 citations · h-index 123
Top works
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors